The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke
Shamalov, N.A.; Stakhovskaia, L.V.; Burenchev, D.V.; Kichuk, I.V.; Tvorogova, T.V.; Botsina, A.I.; Smychkov, A.S.; Kerbikov, O.B.; Moessler, H.; Novak, P.; Skvortsova, V.I.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 110(12 Part 2): 34-37
2010
ISSN/ISBN: 1997-7298 PMID: 21626816 Document Number: 644044
The purpose of this randomized, double-blind, placebo-controlled study was to assess safety and efficacy of cerebrolysin used in dosage 50 ml in acute ischemic stroke. Forty-seven patients with ischemic stroke, aged 45-85 years, who were admitted to a clinical unit within the first 12 h after stroke onset were included in the study. A quantitative time-related MRI analysis of the dynamics of neurological deficit revealed the more rapid decrease of stroke volume to the 28th day in the group treated with cerebrolysin (45.4% versus 43.6% in the placebo-group (p < 0.05)). No side-effects of treatment with cerebrolysin was found. The results of this prospective, randomized, placebo-controlled study suggest the positive effect of cerebrolysin on the dynamics of volume lesion in patients with ischemic stroke.